drug

abaloparatide

Marketedupdated 2mo ago

by Radius Health Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 3, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

Jan 10, 2040method-of-use (U-3322)US 11255842
Jan 10, 2040method-of-use (U-3322)US 11680942
Apr 30, 2038formulationUS 10996208
Apr 30, 2038formulationUS 11782041
Apr 30, 2038formulationUS 11977067
Apr 28, 2031method-of-use (U-2009)US 78037704.8y
Apr 28, 2031method-of-use (U-3543)US RE494444.8y
Nov 8, 2027formulationUS 81483331.3y
Oct 3, 2027method-of-use (U-2009)US 87483821.2y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 47m ago

Found something off?

Trials studying abaloparatide

phase4Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Aloneactive not recruitingn=70
phase4Abaloparatide Before Total Knee Arthroplastycompletedn=58
phase4Supracondylar Distal Femur Fractures and Abaloparatidewithdrawn
—Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Womencompletedn=22,054
phase1Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)completedn=22